Pathology (Board Review Series)
0781760224
9780781760225
Description:
Now in its updated Third Edition, BRS Pathology is an excellent preparatory review for course exams or the USMLE Step 1. Chapters parallel most standard pathology texts and each chapter ends with a review test. Topics covered include general and basic pathology, major concepts of disease processes, and systemic pathology surveying principal disorders of each organ system. A comprehensive examination at the end of the book contains 500 USMLE-format questions. USMLE questions have all been updated to current USMLE format.
The text is written in outline format for effective review. Icons indicate high-yield information that correlates with key pathology concepts.
Best prices to buy, sell, or rent ISBN 9780781760225
Related Books
- 1
- 2
- 3
- 4
- BRS Pathology: International EditionSCHNEIDEREdition:1ISBN-13:9781451109061
- PathologySchneider, Arthur S.; Szanto, Philip A.ISBN-13:9780683076080
- Pathology: Board Review SeriesArthur S. SchneiderEdition:2nd EditionISBN-13:9780683302653
- Pathology (Board Review)Schneider, Arthur S.; Szanto, Philip A.Edition:4ISBN-13:9780781779418
- BRS Pathology: International EditionSCHNEIDEREdition:1ISBN-13:9781451109061
- PathologySchneider, Arthur S.; Szanto, Philip A.ISBN-13:9780683076080
Frequently Asked Questions about Pathology (Board Review Series)
The price for the book starts from $6.35 on Amazon and is available from 24 sellers at the moment.
If you’re interested in selling back the Pathology (Board Review Series) book, you can always look up BookScouter for the best deal. BookScouter checks 30+ buyback vendors with a single search and gives you actual information on buyback pricing instantly.
As for the Pathology (Board Review Series) book, the best buyback offer comes from and is $ for the book in good condition.
The Pathology (Board Review Series) book is in very low demand now as the rank for the book is 5,413,384 at the moment. A rank of 1,000,000 means the last copy sold approximately a month ago.
Not enough insights yet.